Research programme: anti-aging therapeutics - Everon Biosciences
Latest Information Update: 09 Aug 2016
At a glance
- Originator Everon Biosciences
- Class Small molecules
- Mechanism of Action Immunomodulators; Macrophage modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 06 Jul 2016 Preclinical trials in Inflammation in USA (unspecified route)